Nine Years to the Hatchery Floor: Merck's Patient Acquisition of TARGAN

On June 11 Merck Animal Health agreed to acquire TARGAN, a developer of high-speed biological devices for poultry hatcheries. Neither party disclosed terms.

The omission is the wrong place to look. Merck first backed TARGAN in 2017 and has sat among its largest shareholders since. The deal is the last step in a staged accumulation, not a competitive auction win.

The transaction moves Merck from supplying vaccines to owning the hardware that administers them. 

The 2017 investment gave Merck early visibility into a company solving two hatchery problems at once: sorting chicks by sex and vaccinating them one at a time. Neither was solved when Merck first wrote a cheque.

WingScan, the sexing system, matured first. More than 40 units now run across hatcheries in the United States, Canada and Europe, carrying the product from pilot to commercial reference. The precision vaccination device followed and is approaching full launch.

The sequence is consistent with how strategics de-risk hardware bets. Merck held a minority position while the field validated the machines, then took full ownership once the second and more defensible product neared readiness.

Buying earlier would have meant carrying execution risk. Buying later would have invited rival bidders. The timing suggests Merck understood both.

WingScan automates feather sexing on day-old chicks. Multi-spectral cameras image each bird's wings, and machine-learning models classify sex at 97 to 99 percent accuracy, above the roughly 95 percent of manual sorters. A pneumatic mechanism diverts birds into separate lines at up to 160,000 chicks an hour.

The economic case sits downstream. Male and female broilers grow on different curves and need different diets. Sorting them at hatch lets integrators feed each sex to its optimum, improving feed conversion and producing the uniform carcasses that high-speed processing lines require. University of Georgia work put the gain from sex-separate rearing at $48,800 to $330,300 a week for a 1.8m-bird complex.

The vaccination device addresses a separate loss. Conventional spray cabinets drench crates of chicks and achieve individual uptake of 30 to 50 percent. TARGAN's system locates each chick's eye and delivers a 14-microlitre dose to the ocular surface, exceeding 95 percent targeted accuracy at 100,000 birds an hour.

Reliable day-one immunity reduces reliance on in-feed antibiotics and coccidiostats. That aligns with retail demand for antibiotic-free supply.

The two machines combine into a barrier. An integrator that installs the ocular system to capture a 95 percent vaccination rate has a strong reason to run Merck's validated biologics through it. Vaccines designed for coarse mass spray cannot match the delivered performance.

That bundling converts a commodity sale into a defended one. It also lets Merck move pricing away from per-dose economics toward outcome-based terms such as cost-per-protected-bird, supported by hardware it controls.

The constraint is customer concentration. A handful of integrators including Tyson, JBS and BRF command most global capacity. They welcome the uniformity gains and will resist closed bundling that removes their right to run third-party vaccines. How hard Merck presses the lock-in will set the adoption curve.

The acquisition repositions Merck against a specific set of rivals. Zoetis holds the dominant hatchery-device franchise through its Embrex in-ovo injection systems, with more than 600 units installed across 30-plus countries. Embrex works inside the egg around day 18 and remains the standard for Marek's disease. It does not reach the post-hatch ocular and respiratory routes that TARGAN covers, so the two systems sit adjacent rather than head to head.

A separate distinction matters for how the WingScan thesis is read. The European in-ovo sexing firms, Agri Advanced Technologies, Seleggt and Orbem, identify embryo sex inside the egg to cull male layer eggs before hatch. That is a welfare play for the egg-laying industry. WingScan serves the broiler industry, where both sexes are reared for meat and the value is in sorting, not destruction. The technologies do not compete for the same volume.

The clearer pressure lands on Ceva and Elanco. Ceva holds a strong position in hatchery spray and gel delivery and now faces a precision system that outperforms coarse spray on uptake. Expect Ceva to push computer vision and micro-dosing into its existing automated lines. Elanco lacks a proprietary hatchery delivery platform and is the most exposed to a bundled hardware-and-biologic offer. Its likely response is to partner with or acquire an independent vision-and-dosing developer before the gap widens.

The deeper prize is data, and its value is not yet settled.

If TARGAN's systems only log machine speeds and error rates, Merck owns operational telemetry useful for service scheduling. That builds no moat.

If Merck links day-one phenotypes, wing images and individual vaccination records to grow-out performance, processing yield and disease outcomes, it builds a compounding dataset. Each cycle sharpens the models, and rivals without comparable data watch the gap widen.

Integrators know their performance data is valuable and will resist aggregation, demanding local control. The resolution of that fight sets the ceiling on the entire strategy.

Merck pairs the hardware with its M-Trust authentication platform and Hedera-based digital product passports. The relevance is regulatory. The EU's Ecodesign rules will require verifiable passports on most imported goods, and its deforestation regulation forces proof that feed and product avoid deforested land.

A system that captures origin and health records at the point of hatch, then carries them through a tamper-resistant ledger, gives exporters a compliance route and gives Merck a reason to stay embedded beyond the vaccine sale. Whether that becomes a standard or a feature depends on how fast retailers and customs regimes demand it.

Merck's competence is biopharmaceuticals, not field service for heavy machinery operating in dust, humidity and chemical washdown. TARGAN runs an equipment-as-a-service and managed-services model, with around-the-clock monitoring, regional engineering hubs and IP69K washdown-rated hardware. Sustaining that is a logistics business Merck has not run before.

If maintenance economics deteriorate, breakdowns will idle hatchery lines and customers will leave. Service costs running above 40 percent of associated service revenue would make the platform structurally unprofitable.

Technology risk compounds it. WingScan depends on feather-sexable breeds. If genetics firms shift traits, or if low-cost in-ovo sexing scales for broiler eggs before day nine, post-hatch sorting could strand. Field accuracy falling below 93 percent in commercial conditions would remove the economic case on its own.

The favourable path makes ocular delivery the default route for respiratory and coccidiosis programmes, securing Merck's vaccine margins behind owned hardware. Equipment-as-a-service and outcome pricing then turn transactional drug sales into recurring revenue that buffers patent cliffs.

The larger option is species expansion. The core of computer vision, real-time classification and microdose actuation is not specific to poultry. Swine vaccination arrays and automated in-water aquaculture delivery are credible extensions, with internal timelines pointing to 2028 and 2029.

Modelled scenarios place the five-year contribution at $100m to $150m if the asset stays a niche tool, $400m to $600m if WingScan becomes a regional standard, and above $1.2bn if the cross-species and traceability layers take hold.

Three signals will separate the cases. The first is the commercial launch of vaccine programmes formatted and priced for the ocular device, expected late in 2026. The second is multi-site contracts with top-ten integrators in the United States, Canada and Spain through the first half of 2027, which would show integrators accepting the platform on Merck's terms. The third is the first patent filings or pilots for swine and in-water systems around 2028, which would confirm the cross-species thesis is more than a roadmap slide.

The verdict rests on execution Merck has not previously had to demonstrate. The biologics logic is sound. Whether a vaccine company can run a hardware service business at hatchery scale is the open question. The next two years of customer wins and service disclosures will answer it.